Insider Trading April 16, 2026 05:04 PM

Vita Coco Director Sadowsky Disposes $191k in Company Stock

Sale under 10b5-1 plan comes amid recent gains, analyst upgrades and elevated valuation metrics

By Ajmal Hussain COCO
Vita Coco Director Sadowsky Disposes $191k in Company Stock
COCO

Kenneth Sadowsky, a director at The Vita Coco Company, Inc. (NASDAQ: COCO), sold 3,900 shares on April 15, 2026, for roughly $190,827. The transaction, carried out under a pre-arranged Rule 10b5-1 trading plan, reduces his direct holding to 586,566 shares while he retains fully vested options exercisable through January 2, 2030. The sale coincides with strong year-over-year share gains and recent analyst adjustments that reflect optimism about the company's sales trajectory.

Key Points

  • Director Kenneth Sadowsky sold 3,900 Vita Coco shares on April 15, 2026, for roughly $190,827 at prices between $48.50 and $49.34.
  • Following the sale, Sadowsky directly holds 586,566 shares and retains 27,300 fully vested options exercisable at $10.178 until January 2, 2030.
  • Analysts have adjusted views upward - Evercore ISI raised its price target to $70 (Outperform) and Morgan Stanley increased its target to $57 (Equalweight) after revising fiscal 2026 and 2027 adjusted EBITDA estimates upward by 11% and 12% respectively; scanner data showed a 51.1% sales increase for the week ending March 8 attributed to promotions.

Kenneth Sadowsky, who serves on the board of The Vita Coco Company, Inc. (NASDAQ: COCO), executed a sale of 3,900 shares of the company's common stock on April 15, 2026, generating proceeds of approximately $190,827. The shares changed hands at prices between $48.50 and $49.34 per share. The transaction was completed through a pre-arranged Rule 10b5-1 trading plan.

After the sale, Sadowsky's direct ownership stands at 586,566 shares of Vita Coco common stock. In addition to his shareholdings, he holds options to acquire 27,300 shares at an exercise price of $10.178 per share. Those options are fully vested, currently exercisable, and carry an expiration date of January 2, 2030.

The timing of the insider sale arrives against a backdrop of notable stock performance and recent analyst activity. Vita Coco's shares have delivered a 61% gain over the past year, although the stock has softened in the near term and is trading above InvestingPro's Fair Value estimate, a status that places the security on InvestingPro's Most Overvalued list.

Analyst sentiment has shown pockets of heightened optimism. Evercore ISI maintained an Outperform rating on the company and raised its price target from $58 to $70, citing robust sales growth and a favorable outlook for fiscal year 2026. Evercore ISI called out a 51.1% increase in scanner data sales for the week ending March 8, attributing the jump to effective promotional strategies.

Separately, Morgan Stanley lifted its price target for Vita Coco to $57 from $49 while keeping an Equalweight rating. That adjustment coincided with Morgan Stanley increasing its fiscal 2026 and 2027 adjusted EBITDA estimates by 11% and 12%, respectively, revisions the firm made after Vita Coco reported fourth-quarter results in February.

Both Evercore ISI and Morgan Stanley expressed confidence in the company's longer-term growth prospects, with Evercore ISI notably more bullish in its outlook. Collectively, these analyst moves reflect a generally favorable tone toward Vita Coco's future performance while the stock's valuation signals have pushed it onto overvaluation lists maintained by InvestingPro.


Clear summary

Kenneth Sadowsky sold 3,900 shares of Vita Coco on April 15, 2026 under a Rule 10b5-1 plan for about $190,827; he retains 586,566 shares and 27,300 fully vested options exercisable at $10.178 through January 2, 2030. The sale coincides with a 61% year-over-year share gain, recent analyst target increases from Evercore ISI and Morgan Stanley, and a valuation assessment that places the stock above InvestingPro's Fair Value estimate.

Risks

  • Valuation risk - the shares trade above InvestingPro's Fair Value estimate and appear on its Most Overvalued list, indicating potential downside if market sentiment shifts.
  • Sustainability of sales growth - a 51.1% increase in scanner data sales for the week ending March 8 was attributed to promotional activity, creating uncertainty about whether such gains are durable without continued promotional support.
  • Near-term share weakness - while the stock has risen 61% over the past year, it has softened recently, introducing short-term market volatility for investors.

More from Insider Trading

Aehr Test Systems Director Sells $1.21M in Stock as Company Posts Mixed Results and Secures Major Order Apr 16, 2026 Micron Sales by EVP Cordano Total $1.48 Million Amid Strong Share Gains and Mixed Analyst Views Apr 16, 2026 Arista CFO Sells $1.37M in Stock as Analysts Upgrades Highlight AI Demand Apr 16, 2026 Bloom Energy COO Disposes $4.08 Million in Class A Shares; Oracle Pact Expanded Apr 16, 2026 OrbiMed Advisors Disposes $22.9M in Sionna Therapeutics Shares Over Three Days Apr 16, 2026